Evidence map›Paper›PMID 15735978›Full record

ArticleVirchows Archiv : an international journal of pathology2005

Aggressive angiomyxoma: a clinicopathological and immunohistochemical study of 11 cases with long-term follow-up.

J F Graadt van Roggen, J A M van Unnik, I H Briaire-de Bruijn, P C W Hogendoorn

Abstract readCase Reports
PubMed Publisher
In one paragraph

Article in Virchows Archiv : an international journal of pathology, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
1.4field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 88 citations in OpenAlex.

  1. Article
  2. Vulvar Hemangioma: A Review.Diagnostics (Basel, Switzerland) · 2025
    Review
  3. Article
  4. Review
  5. Aggressive angiomyxoma of the epididymis: A case report.World journal of clinical cases · 2023
    Article
  6. Article
  7. Article
  8. Article
  9. Aggressive Angiomyxoma-Report of a Rare Male Buttock Lesion.Plastic and reconstructive surgery. Global open · 2018
    Article
  10. Article
  11. Article
  12. Article
  13. Intravenous leiomyomatosis: an unusual intermediate between benign and malignant uterine smooth muscle tumors.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2016
    Article
  14. Review
  15. Aggressive angiomyxoma of the vulva: a bizarre perineal lesion.Case reports in oncological medicine · 2015
    Article
  16. Life-threatening angiomyxoma of the larynx.Ethiopian journal of health sciences · 2015
    Article
  17. Aggressive angiomyxoma.Indian dermatology online journal · 2014
    Article
  18. Article
  19. Article
  20. Aggressive angiomyxoma of the spermatic cord: A rare entity.Indian journal of urology : IJU : journal of the Urological Society of India · 2009
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

J F Graadt van RoggenDepartment of Pathology, Leiden University Medical Centre, Building I, L1-Q, P.O. Box 9600, 2300RC, Leiden, The Netherlands.
J A M van Unnik
I H Briaire-de Bruijn
P C W Hogendoorn
Leiden University · NLNetherlands Comprehensive Cancer Organisation · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsTo report the clinicopathological and immunohistochemical features and longer term biological behaviour of aggressive angiomyxoma, an uncommon mesenchymal neoplasm occurring predominantly in the pelvi-perineal region of adults. Using immunohistochemistry, possible overexpression of CDK4 and MDM2 was analysed, which might point to (cyto)genetic alteration(s) in chromosome region 12q13-15, an area reported to be altered in this tumour entity. METHODS AND

resultsCases (n=11) of aggressive angiomyxoma were retrieved from the consultation files of the Comprehensive Cancer Centre of the Middle Netherlands (IKMN) panel for soft tissue tumours. Clinical and follow-up information were obtained, and immunohistochemical analysis was performed using antibodies directed against vimentin, cytokeratin AE1/AE3, desmin, alpha-smooth-muscle actin, CD34, S-100 protein, oestrogen receptors, CDK4 and MDM2. Five patients were female (age range 24-47 years; median 39 years), and six patients were male (age range 36-69 years; median 44.5 years). Of 11 cases, 10 arose in the pelvi-perineal area and 1 arose in the abdominal cavity in close relation to the bladder. Morphology was consistent with previous reports of this entity. Immunohistochemically, 8 of 11 cases were desmin positive (5 of 5 positive in females; 3 of 6 positive in males), 6 of 11 cases were positive for alpha-smooth-muscle actin, 5 of 11 cases were CD34 positive, 11 of 11 cases, irrespective of gender, were positive for oestrogen receptors and 3 of 11 cases were positive for cytokeratin AE1/AE3. Strong, diffuse nuclear positivity for CDK4 expression was present in all 6 cases tested, while only 1 of 11 cases tested for MDM2 showed weak focal positivity. Clinical follow-up in all cases (range 1-216 months; median 72 months) showed one local recurrence (9%) after 36 months. No metastases or tumour-related deaths were noted.

conclusionsThe sex distribution of cases reported in this study was roughly equal, in contrast to previous reports emphasising the predominance of this tumour in females. Our study confirms the local aggressive nature of aggressive angiomyxoma, although our local recurrence rate is lower than previous reports (9% versus 36-72%); no metastases and/or disease-related patient deaths were documented. All cases arising in females were positive for desmin, while three of the six cases arising in males were negative for desmin, supporting previous findings and indicating that the lesion may be somewhat different in males. The strong diffuse positivity for CDK4 in all six cases tested goes some way in implicating CDK4, either directly or indirectly, in tumourigenesis. The negative immunostaining for MDM2 would argue against functional amplification of this gene.

Indexed as

ActinsAdultAgedAntigens, CD34Cyclin-Dependent Kinase 4Cyclin-Dependent KinasesDesminFemaleFollow-Up StudiesHumansImmunohistochemistryKeratinsMaleMiddle AgedMyxomaNeoplasm MetastasisActinsAntigens, CD34CDK4 protein, humanCyclin-Dependent Kinase 4Cyclin-Dependent KinasesDesminKeratinsMDM2 protein, humanNuclear ProteinsProto-Oncogene ProteinsProto-Oncogene Proteins c-mdm2Receptors, Estrogen

Identifiers

PMID15735978
OpenAlexW2017073539

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.